PPT-Treatment-Experienced Patients in Resource-Limited Settings

Susan M Graham Assistant Professor Medicine and Global Health Adjunct Assistant Professor Epidemiology Presentation prepared by Susan M Graham Last Updated October 29 2014 Susan M Graham MD MPH PhD. Susan M. Graham . Assistant Professor, Medicine and Global Health. Adjunct Assistant Professor, Epidemiology. Presentation prepared by: . Susan M. Graham. Last Updated: . October 22, 2014. Susan M. Graham, MD MPH PhD. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . Norman & . Bobrow. . (1975). HCI guy collaborates with Comp . Sci. guy and look what happens…. Performance-Resource Functions. (A dynamic family of curves). Performance Operating Characteristics. Settings. Ramona Bhatia, MD. Tuberculosis (TB). Epidemiology. Diagnostics and treatment. Prevention and student health issues . Malaria. Epidemiology. Diagnostics and treatment. Prophylaxis for travelling students. Progress and Challenges. Dr. B. B. . Rewari. MD,FRCP,FICP,FIACM,FGSI,FIAMS,FIMSA. ,. NPO . (. ART) India. 21. st. July 2014, . Adult Guidelines. India. Making of Worlds Second Largest ART Programme . Settings. Ramona Bhatia, MD. Tuberculosis (TB). Epidemiology. Diagnostics and treatment. Prevention and student health issues . Malaria. Epidemiology. Diagnostics and treatment. Prophylaxis for travelling students. When should it be done?. Professor of Medicine. UNC Chapel Hill School of Medicine. Joseph J. Eron, Jr., MD. Disclosures. Principal Investigator (Research Grants to University of North Carolina): GlaxoSmithKline/. BRIGHTE Study (Week 48 Data). Fostemsavir (FTR) for Heavily Treatment Experienced. BRIGHTE Study . (Week 48). : Background. Source: . Kozal. M, et al. N . Engl. J Med. 2020;382:1232-43.. Study Design: BRIGHTE. Sciences (CIOMS) ISBN: 978 - 929036100 - 8 All rights reserved. CIOMS publications may be obtained directly from CIOMS through its publications e - module at https://cioms.ch/publications/. Further Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. 5. th. May 2021 . Elective Withdrawal of Non-Invasive Respiratory Support in the COVID-19 Positive Patient:. A Case Report . Dr Jenny McKeon. . Introduction . Withdrawal of non-invasive respiratory support has been seen frequently in COVID-19 patients. This case report follows two patients who voluntarily withdrew from CPAP therapy, to highlight barriers which may prevent informed patient decisions and common patient factors which may influence patient’s decisions. . Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. POTENT Trial. Tipranavir. /. r . versus Darunavir. /r . in Treatment-Experienced . POTENT. : Study Design. Source: . Elgadi. MM, et al. . Drugs R D. . 2011;11:. 295-. 302.. Tipranavir. . + . R. itonavir BID . POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR .